A recently published paper (17) first demonstrated that serum anti-IGFBP-2 antibody was significantly elevated in gliomas and colorectal carcinoma, suggesting that the detection of circulating anti-IGFBP-2 antibody may be a potential approach in diagnosing early cancers. This evidence concerns the gene IGFBP2 and glioma.